James Vardiman to Dose-Response Relationship, Drug
This is a "connection" page, showing publications James Vardiman has written about Dose-Response Relationship, Drug.
Connection Strength
0.010
-
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
Score: 0.005
-
Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood. 1990 Nov 15; 76(10):1941-5.
Score: 0.004